Bone metastasis occurs in 30–40% of patients with advanced non-small cell lung cancer (NSCLC), and denosumab combined with PD-1/PD-L1 inhibitors has emerged as a promising treatment strategy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.